Axsome Therapeutics AXSM Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $708.24M+63.9% | $638.5M+65.5% | $561.26M+65.8% | $495.03M+69.8% | $432.16M+72.2% | ||
| $52.41M+42.4% | $47.48M+42.6% | $45.66M+51.4% | $42.19M+49.3% | $36.8M+48.3% | ||
| $655.82M+65.9% | $591.02M+67.7% | $515.6M+67.2% | $452.85M+72.0% | $395.36M+74.8% | ||
| 92.6%+1.1pp | 92.6%+1.2pp | 91.9%+0.8pp | 91.5%+1.2pp | 91.5%+1.4pp | ||
| $191.17M-2.0% | $183.28M-2.0% | $189.49M+16.3% | $194.72M+33.1% | $195.03M+66.7% | ||
| $634.81M+46.5% | $570.6M+38.7% | $514.57M+33.7% | $459.9M+23.5% | $433.18M+24.5% | ||
| $6.38M0.0% | $6.38M-0.3% | $6.38M-0.3% | $6.37M-0.3% | $6.38M-0.3% | ||
| $881.37M+25.5% | $805.26M+20.9% | $773.69M+20.0% | $723.97M+21.2% | $702.43M+29.2% | ||
| -$173.14M+35.9% | -$166.76M+40.6% | -$212.42M+30.6% | -$228.94M+25.1% | -$270.27M+7.7% | ||
| -24.4%+38.1pp | -26.1%+46.6pp | -37.8%+52.6pp | -46.2%+58.6pp | -62.5%+54.1pp | ||
| -$5.31M+32.9% | -$6.56M+0.2% | -$7.6M-50.1% | -$8.45M-120% | -$7.92M-50.2% | ||
| -$188.83M+32.1% | -$183.7M+36.0% | -$230.4M+26.0% | -$247.78M+20.0% | -$278.19M+6.6% | ||
| —— | —— | -$875K— | -$875K— | $85K— | ||
| -$188.3M+32.3% | -$183.17M+36.2% | -$229.53M+26.2% | -$246.9M+20.0% | -$278.27M+6.1% | ||
| -26.6%+37.8pp | -28.7%+45.8pp | -40.9%+51.0pp | -49.9%+56.0pp | -64.4%+53.7pp | ||
| -$3.72+35.5% | -$3.68+38.6% | -$4.67+29.0% | -$5.07+22.7% | -$5.77+10.3% | ||
| -$3.72+35.5% | -$3.68+38.6% | -$4.67+29.0% | -$5.07+22.7% | -$5.77+10.3% | ||
| 200.4M+4.1% | 198.1M+3.7% | 196.2M+4.1% | 194.4M+3.7% | 192.5M+4.8% | ||
| 200.4M+4.1% | 198.1M+3.7% | 196.2M+4.1% | 194.4M+3.7% | 192.5M+4.8% | ||
| -$3.4M-111% | -$2.47M-109% | $17.58M-70.9% | $20.79M-52.5% | $31.05M-34.9% | ||
| $6.38M0.0% | $6.38M-0.3% | $6.38M-0.3% | $6.37M-0.3% | $6.38M-0.3% | ||
| -$5.31M+32.9% | -$6.56M+0.2% | -$7.6M-50.1% | -$8.45M-120% | -$7.92M-50.2% | ||
| $708.24M+63.9% | $638.5M+65.5% | $561.26M+65.8% | $495.03M+69.8% | $432.16M+72.2% | ||
| -$173.14M+35.9% | -$166.76M+40.6% | -$212.42M+30.6% | -$228.94M+25.1% | -$270.27M+7.7% | ||
| -$166.29M+36.9% | -$159.88M+41.6% | -$205.53M+31.3% | -$222.03M+25.7% | -$263.35M+7.9% | ||
| -$166.29M+36.9% | -$159.88M+41.6% | -$205.53M+31.3% | -$222.03M+25.7% | -$263.35M+7.9% | ||
| -23.5%+37.5pp | -25%+45.9pp | -36.6%+51.8pp | -44.9%+57.6pp | -60.9%+52.9pp | ||
| -$173.14M+35.9% | -$166.76M+40.6% | -$212.42M+30.6% | -$228.94M+25.1% | -$270.27M+7.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Axsome Therapeutics's revenue?
- Axsome Therapeutics (AXSM) generated $708.2M in revenue over the trailing twelve months, up 63.9% year over year.
- Is Axsome Therapeutics profitable?
- Axsome Therapeutics is not currently profitable: it reported a net loss of $188.3M over the trailing twelve months, a -26.6% net margin.
- What are Axsome Therapeutics's profit margins?
- Gross margin is 92.6% and operating margin is -24.4%, with a -26.6% net margin.
- What is Axsome Therapeutics's earnings per share?
- Axsome Therapeutics's diluted EPS over the trailing twelve months is $-3.72.
- Where does Axsome Therapeutics's income statement data come from?
- Every line is extracted from Axsome Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
